Navigation Links
YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
Date:2/10/2011

plasms and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that our JAK1/JAK2 inhibitor CYT387 and our VDA small molecule CYT997
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
3. YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
4. Ardea Biosciences Prices Public Offering of Common Stock
5. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
6. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
7. Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students
8. YM BioSciences Closes Public Offering of Common Shares
9. YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING
10. Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen
11. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... 2014 As pet owners drew up their lists of New ... "Take better care of my furry companion." Nowadays there are pet ... carrying cases to take the little canine or feline darlings along ... to buy some pricey toys at the pet store. But anyone ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... NES-ZIONA, Israel, Sept. 21 PROLOR Biotech, Inc. (OTC ... of a Phase I clinical trial of its long-acting human ... hGH-CTP is being developed to provide growth hormone deficient adults ... per week that are currently required with a once-weekly or ...
... prolonged courses of stable disease and excellent, ... cancer, , , QUEBEC CITY, Sept. ... AEZS ) ("the Company"), a global biopharmaceutical company focused ... a Phase 1 study of its orally-active tubulin and topoisomerase ...
... ... most reliable and secure professional solution to inventory Ultra-low Freezer and Liquid Nitrogen Tank ... ... 21, 2009 -- RURO Inc. today announced the release of FreezerPro 2010, Frozen ...
Cached Biology Technology:PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone 2PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone 3PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone 4AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer 2AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer 3RURO Inc. Today Announced the Release of FreezerPro 2010, Frozen Sample Inventory and Information Management System 2
(Date:4/22/2014)... 2014) -- There are all sorts of signaling strategies ... their colorful tails; satin bowbirds build specialized stick structures, ... objects; and European bitterling males show off bright nuptial ... unique method to communicate with others. , ... can have profound fitness implications for individuals that are ...
(Date:4/22/2014)... University of Montana,s Wildlife Biology Program, co-wrote a research paper ... Academy of Sciences on how streamwater chemistry varies across ... Lowe and co-authors ... Washington, the Cary Institute of Ecosystem Studies, the University of ... 664 water samples collected every 10 meters along 32 tributaries ...
(Date:4/22/2014)... 22, 2014) Biotechnology scientists must be aware of ... and licensing guidelines, according to a new paper from ... in the current issue of the journal Regenerative ... 2013 U.S. Supreme Court ruling in the case Association ... occurring genes are unpatentable. The court case and rulings ...
Breaking Biology News(10 mins):Best practices in communication for the animal world 2Best practices in communication for the animal world 3New research focuses on streamwater chemistry, landscape variation 2New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... April 30, 2012 It is often thought that starting ... they try to set a good example for their children. ... children into the home may affect parents, eating habits. ... a child,s eating preferences may influence how a family eats. ...
... Efforts to prevent obesity among low-income infants should focus not ... reasons behind unhealthy feeding practices, according to a study to ... (PAS) annual meeting in Boston. Adding cereal to bottles ... Academy of Pediatrics because it may lead to overfeeding and ...
... Calif. Avocado, a significant fruit crop grown in ... threatened by Phytophthora root rot (PRR), a disease that ... in Latin America and crippled production in Australia and ... estimated to cost avocado growers approximately $30-40 million a ...
Cached Biology News:Starting a family does not encourage parents to eat healthier 2Low-income moms under stress may overfeed infants 2New avocado rootstocks are high-performing and disease-tolerant 2New avocado rootstocks are high-performing and disease-tolerant 3
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
ANTI ALPHA FSH:B...
... Dog serum is collected from fasted mixed breed, ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
MOUSE ANTI BOVINE TROPONIN I...
Biology Products: